Shares of Pfizer Ltd surged 5.83% to Rs 5,308 on Thursday, November 13, after the company reported a solid set of earnings for the quarter ended September 2025 (Q2 FY26), driven by higher sales and improved operational efficiency.
The company’s net profit rose 19.4% year-on-year (YoY) to Rs 189.02 crore, compared to Rs 158.3 crore in the same period last year. However, on a sequential basis, profit dipped 1.4%.
Revenue from operations stood at Rs 642.34 crore, up 9.1% YoY and 6.5% QoQ. The company’s total income grew 8.3% YoY to Rs 684.19 crore, despite a 2.8% YoY decline in other income to Rs 41.85 crore.
Profit before tax (PBT) rose 18.7% YoY to Rs 255.37 crore, while total expenses increased marginally by 3% YoY to Rs 428.82 crore, indicating improved cost control.
On the operational front, employee benefit expenses fell 6% YoY to Rs 94.67 crore, while depreciation and amortization costs were slightly lower at Rs 14.28 crore versus Rs 14.99 crore a year earlier. The company also recorded an inventory adjustment gain of Rs 63.32 crore, boosting gross margins.
The strong quarterly performance pushed Pfizer’s stock to a new intraday high, reflecting positive investor sentiment toward its consistent earnings growth and cost optimization efforts.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
